Jazz Pharmaceuticals price target raised to $207 from $171 at Brean Capital Brean Capital raised its price target on Jazz Pharmaceuticals following Q4 earnings and the EU approval of its Defibrio drug. Shares are Buy rated.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Allergan merger deal not imminent, CNBC's Faber reports An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.